Literature DB >> 10388983

Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes.

S D Sibley1, J E Hokanson, M W Steffes, J Q Purnell, S M Marcovina, P A Cleary, J D Brunzell.   

Abstract

OBJECTIVE: This population study examines the relationship between LDL density and persistent albuminuria in subjects with type 1 diabetes at the end of the Diabetes Control and Complications Trial (DCCT). RESEARCH DESIGN AND METHODS: Subjects were classified as persistently normoalbuminuric (albumin excretion rate [AER] < 30 mg/d, n = 1,056), microalbuminuric (AER > or = 30-299 mg/day, n = 80), and macroalbuminuric (AER = 300 mg/day, n = 24) based on the last two AER measures.
RESULTS: Triglyceride (P < 0.01) and LDL cholesterol (P < 0.01) levels were higher in macroalbuminuric subjects compared with normoalbuminuric subjects. Cholesterol distribution by density-gradient ultracentrifugation showed an increase in intermediate-density lipoprotein (IDL) and a shift in peak LDL from buoyant toward more dense particles with progressive albuminuria. In the entire group, there was a significant negative correlation between the peak buoyancy of LDL particles and albuminuria (r = -0.238, P < 0.001, n = 1,160). This correlation persisted in the normoalbuminuric DCCT group (r = -0.138, P < 0.001, n = 1,056).
CONCLUSIONS: As albuminuria increases in subjects with type 1 diabetes, dyslipidemia occurs with an increase in IDL and dense LDL that may lead to increased cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10388983      PMCID: PMC2635089          DOI: 10.2337/diacare.22.7.1165

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  35 in total

1.  Microalbuminuria and associated cardiovascular risk factors in the community.

Authors:  P H Winocour; J O Harland; J P Millar; M F Laker; K G Alberti
Journal:  Atherosclerosis       Date:  1992-03       Impact factor: 5.162

2.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material.

Authors:  S M Marcovina; J J Albers; L O Henderson; W H Hannon
Journal:  Clin Chem       Date:  1993-05       Impact factor: 8.327

3.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

4.  Pattern of hyperlipoproteinemia in human nephrotic syndrome: influence of renal failure and diabetes mellitus.

Authors:  J Joven; C Villabona; E Vilella
Journal:  Nephron       Date:  1993       Impact factor: 2.847

5.  Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study.

Authors:  J W Messent; T G Elliott; R D Hill; R J Jarrett; H Keen; G C Viberti
Journal:  Kidney Int       Date:  1992-04       Impact factor: 10.612

6.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material.

Authors:  S M Marcovina; J J Albers; H Kennedy; J V Mei; L O Henderson; W H Hannon
Journal:  Clin Chem       Date:  1994-04       Impact factor: 8.327

7.  Baseline analysis of renal function in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group [corrected].

Authors:  M E Molitch; M W Steffes; P A Cleary; D M Nathan
Journal:  Kidney Int       Date:  1993-03       Impact factor: 10.612

8.  Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial.

Authors: 
Journal:  Am J Cardiol       Date:  1995-05-01       Impact factor: 2.778

9.  Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a).

Authors:  S M Marcovina; J J Albers; B Gabel; M L Koschinsky; V P Gaur
Journal:  Clin Chem       Date:  1995-02       Impact factor: 8.327

10.  LDL subclasses in IDDM patients: relation to diabetic nephropathy.

Authors:  S Lahdenperä; P H Groop; M Tilly-Kiesi; T Kuusi; T G Elliott; G C Viberti; M R Taskinen
Journal:  Diabetologia       Date:  1994-07       Impact factor: 10.122

View more
  11 in total

1.  Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.

Authors:  Alicia J Jenkins; Jeremy Yu; Petar Alaupovic; Arpita Basu; Richard L Klein; Maria Lopes-Virella; Nathaniel L Baker; Kelly J Hunt; Daniel T Lackland; W Timothy Garvey; Timothy J Lyons
Journal:  J Diabetes Complications       Date:  2013-07-11       Impact factor: 2.852

2.  Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria.

Authors:  Carol Forsblom; Valma Harjutsalo; Lena M Thorn; Johan Wadén; Nina Tolonen; Markku Saraheimo; Daniel Gordin; John L Moran; Merlin C Thomas; Per-Henrik Groop
Journal:  J Am Soc Nephrol       Date:  2011-02-18       Impact factor: 10.121

3.  Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study.

Authors:  Ian H de Boer; Shalamar D Sibley; Bryan Kestenbaum; Joshua N Sampson; Bessie Young; Patricia A Cleary; Michael W Steffes; Noel S Weiss; John D Brunzell
Journal:  J Am Soc Nephrol       Date:  2006-12-06       Impact factor: 10.121

4.  Strawberries decrease atherosclerotic markers in subjects with metabolic syndrome.

Authors:  Arpita Basu; Dong Xu Fu; Marci Wilkinson; Brandi Simmons; Mingyuan Wu; Nancy M Betts; Mei Du; Timothy J Lyons
Journal:  Nutr Res       Date:  2010-07       Impact factor: 3.315

5.  Effect of glycated LDL on microvascular tone in mice: a comparative study with LDL modified in vitro or isolated from diabetic patients.

Authors:  P Nivoit; N Wiernsperger; P Moulin; M Lagarde; C Renaudin
Journal:  Diabetologia       Date:  2003-10-24       Impact factor: 10.122

6.  Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric Type 1 diabetic patients.

Authors:  T Bulum; B Kolaric; L Duvnjak
Journal:  J Endocrinol Invest       Date:  2013-02-12       Impact factor: 4.256

Review 7.  Is proteinuria a plausible target of therapy?

Authors:  Dave C Y Chua; George L Bakris
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

Review 8.  Cardiovascular disease and type 1 diabetes: prevalence, prediction and management in an ageing population.

Authors:  Siang Ing Lee; Mitesh Patel; Christopher M Jones; Parth Narendran
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

9.  Mild elevations of urine albumin excretion are associated with atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Ian H de Boer; Brad C Astor; Holly Kramer; Walter Palmas; Kyle Rudser; Stephen L Seliger; Michael G Shlipak; David S Siscovick; Michael Y Tsai; Bryan Kestenbaum
Journal:  Atherosclerosis       Date:  2007-08-06       Impact factor: 5.162

Review 10.  Microalbuminuria: what is it? Why is it important? What should be done about it?

Authors:  G L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Mar-Apr       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.